Get the Stockscreener App
36.85
0.23%
-0.085
After Hours:
37.01
0.155
+0.42%
Exelixis Inc stock is traded at $36.85, with a volume of 5.15M.
It is down -0.23% in the last 24 hours and down -15.61% over the past month.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
See More
Previous Close:
$36.94
Open:
$37.135
24h Volume:
5.15M
Relative Volume:
1.47
Market Cap:
$10.05B
Revenue:
$2.17B
Net Income/Loss:
$521.27M
P/E Ratio:
20.82
EPS:
1.77
Net Cash Flow:
$633.79M
1W Performance:
-18.82%
1M Performance:
-15.61%
6M Performance:
+11.92%
1Y Performance:
+58.38%
1-Day Range:
$36.85
$37.98
1-Week Range:
$36.81
$46.43
52-Week Range:
$23.13
$49.62
Exelixis Inc Stock (EXEL) Company Profile
Name
Exelixis Inc
Sector
Industry
Phone
(650) 837-7000
Address
1851 HARBOR BAY PARKWAY, ALAMEDA, CA
Compare EXEL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EXEL
Exelixis Inc
|
36.85 | 9.94B | 2.17B | 521.27M | 633.79M | 1.77 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.16 | 120.29B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
554.58 | 60.26B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
339.80 | 43.10B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
598.89 | 36.65B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.94 | 33.09B | 3.81B | -644.79M | -669.77M | -6.24 |
Exelixis Inc Stock (EXEL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-08-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jun-24-25 | Upgrade | Stephens | Equal-Weight → Overweight |
| Feb-24-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jan-27-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-24-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Dec-20-24 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Dec-17-24 | Downgrade | BofA Securities | Buy → Neutral |
| Oct-16-24 | Reiterated | RBC Capital Mkts | Outperform |
| Sep-19-24 | Initiated | UBS | Neutral |
| Apr-11-24 | Downgrade | Barclays | Overweight → Equal Weight |
| Dec-19-23 | Initiated | BTIG Research | Buy |
| Dec-15-23 | Initiated | Citigroup | Buy |
| Sep-26-23 | Initiated | H.C. Wainwright | Buy |
| Aug-22-23 | Reiterated | Oppenheimer | Outperform |
| Aug-08-23 | Initiated | SVB Securities | Market Perform |
| Jul-11-23 | Resumed | Morgan Stanley | Equal-Weight |
| May-10-23 | Resumed | Piper Sandler | Overweight |
| Mar-09-23 | Initiated | Wells Fargo | Overweight |
| Jan-26-23 | Initiated | Credit Suisse | Outperform |
| Oct-18-22 | Initiated | JMP Securities | Mkt Outperform |
| Jun-24-22 | Initiated | BMO Capital Markets | Outperform |
| Nov-19-21 | Initiated | Piper Sandler | Overweight |
| Nov-03-21 | Resumed | Jefferies | Buy |
| Oct-07-21 | Initiated | Jefferies | Buy |
| Aug-06-21 | Reiterated | H.C. Wainwright | Buy |
| Jun-15-21 | Initiated | H.C. Wainwright | Buy |
| May-18-21 | Resumed | Goldman | Sell |
| Mar-31-21 | Initiated | Credit Suisse | Outperform |
| Mar-12-21 | Initiated | Wolfe Research | Outperform |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Jan-13-20 | Initiated | SunTrust | Buy |
| Nov-13-19 | Initiated | BofA/Merrill | Buy |
| Mar-18-19 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Sep-17-18 | Initiated | Goldman | Neutral |
| Sep-10-18 | Initiated | Morgan Stanley | Underweight |
| May-11-18 | Reiterated | Needham | Buy |
| Oct-17-17 | Reiterated | Needham | Buy |
| Oct-17-17 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-16-17 | Reiterated | SunTrust | Buy |
| Sep-22-17 | Downgrade | Leerink Partners | Outperform → Mkt Perform |
| Sep-15-17 | Initiated | RBC Capital Mkts | Outperform |
| Sep-12-17 | Reiterated | Needham | Buy |
| Jul-14-17 | Initiated | SunTrust | Buy |
| Mar-31-17 | Initiated | Needham | Buy |
| Mar-16-17 | Initiated | Oppenheimer | Perform |
| Feb-28-17 | Downgrade | Stifel | Buy → Hold |
| Nov-03-16 | Initiated | Deutsche Bank | Buy |
| Oct-10-16 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Sep-15-16 | Reiterated | Stifel | Buy |
View All
Exelixis Inc Stock (EXEL) Latest News
Is Exelixis Inc. a Top Dividend Stock to Watch in 2025Entry and Exit Strategy Optimizer Tool Tested - metal.it
Is Exelixis (EXEL) a Solid Growth Stock? 3 Reasons to Think "Yes" - Yahoo Finance
EXEL Q2 Earnings Top, Sales Miss on Lower Collaboration Revenues - MSN
Exelixis (EXEL) Tumbles 16.8% as Q2 Earnings Disappoint - Insider Monkey
Exelixis, Inc. (NASDAQ:EXEL) Q2 2025 Earnings Call Transcript - Insider Monkey
Exelixis Inc. Forms Double Bottom Pattern — Eyes on BreakoutConservative Long Term Growth Plans Under Review - metal.it
Morgan Stanley Maintains a Buy on Exelixis (EXEL) With a $48 PT - MSN
U.S. Indexes Decreased Tuesday; Exelixis Posted Biggest Loss - Barron's
Exelixis outlines continued cabozantinib growth and zanzalintinib pipeline acceleration as new launches drive 19% revenue increase - MSN
Exelixis stock price target lowered to $45 at RBC on lifecycle cuts - Investing.com Canada
Truist Securities lowers Exelixis stock price target to $49 on mixed results - Investing.com Canada
Exelixis stock price target raised to $41 from $38 at Stifel on NET launch - Investing.com Canada
Exelixis Stuns Analyst With Q2 Miss, Trial Delays, Phase 3 HaltExelixis (NASDAQ:EXEL) - Benzinga
All You Need to Know About Exelixis (EXEL) Rating Upgrade to Strong Buy - Yahoo Finance
Is Exelixis Inc. Forming a Consolidation BaseTop Performing Stock Insights Released Daily - metal.it
Exelixis leans on zanzalintinib as cabozantinib nears patent expiry - S&P Global
Exelixis shares tumble over 12% after revenue miss and zanzalintinib trial halt - MSN
Whirlpool Posts Downbeat Earnings, Joins Harmonic, Stanley Black & Decker And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Benzinga
S&P 500 Futures Climb in Premarket Trading; Whirlpool, Exelixis Lag - Barron's
Exelixis fall over 12% after revenue miss, halts zanzalintinib trial By Investing.com - Investing.com India
UnitedHealth, Sarepta, UPS, Whirlpool, VeriSign, Cadence Design, Exelixis, and More Market Movers - Barron's
Exelixis stock rating reiterated by JMP analyst despite sales miss - Investing.com Nigeria
Exelixis Shares Plunge 12.14% on Revenue Miss - AInvest
Exelixis 2025 Q2 Earnings Mixed Performance as Net Income Declines 18% - AInvest
Exelixis Q2 Revenue Falls 11 Percent - AOL.com
Exelixis Inc (EXEL) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Challenges - Yahoo Finance
Exelixis Inc (EXEL) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Challenges By GuruFocus - Investing.com Canada
Exelixis’s SWOT analysis: cabo success, zanza potential drive stock outlook - Investing.com
Exelixis Reports Q2 2025 Financial Results and Updates - TipRanks
Exelixis: Q2 Earnings Snapshot - The Washington Post
Exelixis Beats On Earnings As Cancer Drugs Drive Growth - Finimize
Earnings call transcript: Exelixis beats EPS forecasts in Q2 2025 - Investing.com
Exelixis slides 12% on Q2 miss, pipeline update (EXEL:NASDAQ) - Seeking Alpha
Exelixis Announces Second Quarter 2025 Financial Results and Provides Corporate Update - BioSpace
After-hours movers: Western Union, Whirlpool, Exelixis, and more By Investing.com - Investing.com Canada
Exelixis (EXEL) Beats Q2 Earnings Estimates - Yahoo Finance
Exelixis Q2 Earnings: Surpassing Expectations Amid Revenue ChallengesNews and Statistics - IndexBox
How strong is Exelixis Inc. company’s balance sheetRetirement Planning Insights For 2025 - jammulinksnews.com
EXELIXIS, INC. SEC 10-Q Report - TradingView
Exelixis shares tumble as revenue miss and weak guidance disappoint - Investing.com Australia
Exelixis shares tumble as revenue miss and weak guidance disappoint By Investing.com - Investing.com India
Exelixis earnings beat by $0.11, revenue fell short of estimates - Investing.com Canada
Exelixis Q2 2025 Financial Results and Corporate Update - TradingView
Exelixis Q2 adjusted EPS beats expectations - MarketScreener
Should I hold or sell Exelixis Inc. stock in 2025Top Growth Entry Points For Every Investor - jammulinksnews.com
Here's Why Exelixis (EXEL) is a Strong Momentum Stock - sharewise.com
Published on: 2025-07-28 16:17:28 - metal.it
Is it the right time to buy Exelixis Inc. stockSuperior returns - jammulinksnews.com
How many analysts rate Exelixis Inc. as a “Buy”Capitalize on proven trading setups - jammulinksnews.com
Why is Exelixis Inc. stock attracting strong analyst attentionSwing Trade Opportunities From AI Tools - jammulinksnews.com
Exelixis, Inc. (EXEL) Stock Analysis: A Biotech Powerhouse with a 30% Revenue Growth Surge - DirectorsTalk Interviews
Exelixis Inc Stock (EXEL) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.23%
0.40%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):